Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) Gross Margin: 2023-2025

Historic Gross Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to 58.45%.

  • Tonix Pharmaceuticals Holding's Gross Margin rose 1355.00% to 58.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.31%, marking a year-over-year increase of 1357.00%. This contributed to the annual value of 23.07% for FY2024, which is 1589.00% down from last year.
  • Tonix Pharmaceuticals Holding's Gross Margin amounted to 58.45% in Q3 2025, which was up 191.67% from -63.76% recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Gross Margin high stood at 61.18% for Q1 2025, and its period low was -63.76% during Q2 2025.
  • Moreover, its 3-year median value for Gross Margin was 40.49% (2023), whereas its average is 23.71%.
  • The largest annual percentage gain for Tonix Pharmaceuticals Holding's Gross Margin in the last 5 years was 2,806bps (2025), contrasted with its biggest fall of 1,127bps (2025).
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Gross Margin (Quarterly) stood at 37.36% in 2023, then surged by 1,682bps to 54.18% in 2024, then skyrocketed by 1,355bps to 58.45% in 2025.
  • Its Gross Margin was 58.45% in Q3 2025, compared to -63.76% in Q2 2025 and 61.18% in Q1 2025.